



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hideaki Imamura, et al.

Serial No. 10/565,327

Filed: January 20, 2006


For: CRYSTALLINE
6-N-PYRIDYLMETHYLAMINOINDOLOCARBAZOLE
COMPOUNDSArt Unit: To be determinedExaminer: To be determinedCommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By  Date 8/1/06

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B./

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: David A. Muthard
Attorney _____ For Applicant(s)

Reg. No. 35,297
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594-3903

Date: August 1, 2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B./



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hideaki Imamura, et al.

Serial No.: 10/565,327 Case No.: BY0018YP

Filed: January 20, 2006

For: CRYSTALLINE FORMS OF 6-N-PYRIDIYLMETHYLAMINOINDOLOCARBAZOLE COMPOUNDS

Art Unit:
To be determined

Examiner:
To be determined

Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

EXPLANATION OF RELEVANCE OF NON-ENGLISH DOCUMENTS UNDER 37
C.F.R. 1.98(a)(3)(i)

Sir:

Applicants respectfully note that two (2) of the documents listed on the USPTO 1449 for submitted herewith is not in the English language and a copy of an English translations of that documents is not within the possession, custody or control of Applicants, and, to the Applicants knowledge, is not readily available. Below is a concise explanation of the relevance of those non-English documents:

The Japanese patent publication JP 6-128283 discloses preparation of a series of 5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5,7(6H)-dione compounds having a substituted amine substituent on the amine of the fused carbazole dione ring. The compounds disclosed therein are described as anti-tumor compounds. There is no specific disclosure in the JP 6-128283 publication of pyridylalkylamine, furylalkylamine or thienylalkylamine substituents on the amine of the fused carbazol dione ring.


The PCT patent publication WO96/04293 discloses preparation of a series of 5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5,7(6H)-dione compounds having a substituted amine substituent on the amine of the fused carbazole dione ring. The compounds disclosed therein are described as anti-tumor compounds. There is no specific disclosure in the WO96/04293 publication of pyridylalkylamine, furylalkylamine or thienylalkylamine substituents on the amine of the fused carbazol dione ring.

The instant invention discloses novel polymorphic forms of a several 5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5,7(6H)-dione compounds having substituted and unsubstituted pyridylalkylamine substituents on the amine of the fused carbazol dione ring.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

By:  DATE: 8/1/06

Respectfully submitted,



David A. Muthard
Reg. No. 35,297
Attorney for Applicant(s)
MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3903

Date: August 1, 2006

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

AUG 07 2006

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/565,327
Filing Date	January 20, 2006
First Named Inventor	Hideaki Imamura
Group Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	BY0018YP

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		PCT	WO 96/04293 (Explanation Att.)		Banyu Pharmaceutical Co., Ltd.	11/16/1995
		EPO	EP 528030		Banyu Pharmaceutical Co., Ltd.	09/17/1997
		JPO	JP 10-245390(Eng. Trans. Att.)		Banyu Pharmaceutical Co., Ltd.	09/14/1998
		JPO	JP 6-128283 (Explanation Att.)		Banyu Pharmaceutical Co., Ltd.	05/10/1994

Examiner
Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. (Draw for thorough citation if not in conformance and note provisions). Include copy of this form with next communication to applicant.

REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B./

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folders, Merck & Co., Inc., 7/12/2005)

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 7/12/2005

